Guo, Linlin
Kaumaya, Pravin T. P. http://orcid.org/0000-0002-8647-3911
Article History
Received: 5 January 2021
Revised: 22 February 2021
Accepted: 4 March 2021
First Online: 26 March 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: All the data relevant to this manuscript are included in the article or in our previous publications (see refs. <sup>6,7</sup>). Other data information’s available on reasonable request from the corresponding author.
: P.T.P.K. is co-inventor on patents regarding PD1-Vaxx which has licensed such patents from OSU to Imugene Ltd. P.T.P.K. has partial inventor rights to PD1-Vaxx which has been licensed for commercial development. P.T.P.K. is consultant to Imugene Ltd. L.G. declares no competing interests. No writing assistance was utilised in the production of this manuscript.
: Funded by National Institutes of Health NIH CA84356, NIH R21CA13508 and Imugene Ltd to P.T.P. Kaumaya.